Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
Abstract
This prospective, randomized, placebo-controlled trial tested green-lipped mussel oil (PCSO-524) added to sildenafil-based therapy in dogs with pulmonary hypertension (PH), mostly secondary to myxomatous mitral valve disease. After 70 days, owner-assessed exercise tolerance improved significantly in the PCSO-524 group (P = 0.009), and the improvement in coughing between Day 35 and Day 70 was greater than with placebo (P = 0.03). The tricuspid regurgitation pressure gradient (TRPG), an echocardiographic estimate of pulmonary arterial pressure, fell in all dogs (P = 0.001), with no difference between groups.
Use of PCSO-524®(Antinol®) in a Pomeranian Dog with Degenerative Mitral Valve Disease (DMVD) and Cardiac Tumor of the Left Atrium
Authors:
A 10-year old Pomeranian dog with degenerative mitral valve disease (DMVD) and cardiac tumor of the left atrium was treated with pimobendan, ramipril, and furosemide in conjunction with PCSO-524® (Antinol®) as supplemental therapy.
After the treatment, the dog showed improved ability to conduct various activities, increased appetite and ingestion, weight gain and disappearance of paroxysmal ventricular premature contraction (VPC).
The C-reactive protein (CRP), which is an inflammatory marker in dogs, also decreased to normal level within 21 days of PCSO-524® (Antinol®) supplementation.
PCSO-524® (Antinol®) Use in Persian Cat with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM)
Authors:
A Persian cat aged 21 years was diagnosed with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM) and treated with PCSO-524® (Antinol®) for 45 days.
The cat regained quality of life and daily activities such as grooming and walking, increased appetite, ingestion and weight gain after the treatment. Serum Amyloid A (SAA), which is an inflammatory marker in cats, was reduced down to normal after 15 days of PCSO-524® (Antinol®) administration.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
